Close Menu

database

Researchers at the Manchester Centre for Genomic Medicine are using the platform to identify genetic alterations tied to cancer and developmental disorders and disabilities.

The companylaunched GenomeStack, its first product for the life science market, earlier this year at the Bio-IT World Conference and Expo in Boston.

The tool uses whole genome sequence from M. tuberculosis strains to predict genetic resistance to tuberculosis drugs faster than traditional culture-based methods.

CICGD scientists will use the NextCode technology to accelerate research, clinical diagnosis, and treatment of rare inherited diseases and malignant tumors. 

The company made the move after several media outlets falsely reported that Ancestry had divulged the identify of a donor without a police warrant.

ARUP's database is one of many options that researchers and oncologists can use to learn about whether alterations in BRCA genes are associated with hereditary breast and ovarian cancer risk.

Under the terms of the agreement, SolveBio will distribute OncoMD, MedGenome's cancer mutation knowledgebase.

The privately-held German firm also plans to offer genetic tumor profiling and noninvasive prenatal testing.

HHS has filed an application with the USPTO to service mark the moniker "precision medicine initiative" and distinguish the government effort from other projects.

A $4.6 million Simons Foundation grant will fund enrollment and initial data collection, but additional resources are necessary for genetic analysis and hypothesis generation.

Pages

A new paper says an effort to introduce gene drives into mosquitos altered the genetic makeup of the local mosquitos, but the company behind the project says the paper is flawed.

Virginia's Department of Forensic Science is offering attorneys a course on DNA testing, the Virginian-Pilot reports.

Researchers examine changes in the genomes of emmer wheat populations where the climate has warmed, the BBC reports.

In Cell this week: microinjection of CRISPR-Cas9 enables targeted mutations in Anolis, melanoma proteomic profiling, and more.